Related references
Note: Only part of the references are listed.Therapeutic targeting of undruggable MYC
Victor Llombart et al.
EBIOMEDICINE (2022)
KRAS-dependent cancer cells promote survival by producing exosomes enriched in Survivin
Wen-Hsuan Chang et al.
CANCER LETTERS (2021)
Stopping the beating heart of cancer: KRAS reviewed
Lorenz Herdeis et al.
CURRENT OPINION IN STRUCTURAL BIOLOGY (2021)
Identification of MRTX1133, a Noncovalent, Potent, and Selective KRASG12D Inhibitor
Xiaolun Wang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Diverse alterations associated with resistance to KRAS(G12C) inhibition
Yulei Zhao et al.
NATURE (2021)
KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro Experiments
Takamasa Koga et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
The long journey to bring a Myc inhibitor to the clinic
Jonathan R. Whitfield et al.
JOURNAL OF CELL BIOLOGY (2021)
Acquired Resistance to KRASG12C Inhibition in Cancer
M. M. Awad et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)
Daniel J. Klionsky et al.
AUTOPHAGY (2021)
BIRC5/Survivin is a novel ATG12?ATG5 conjugate interactor and an autophagy-induced DNA damage suppressor in human cancer and mouse embryonic fibroblast cells
Tzu-Yu Lin et al.
AUTOPHAGY (2020)
The KRAS(G12C) Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients
Jill Hallin et al.
CANCER DISCOVERY (2020)
Discovery of a Covalent Inhibitor of KRASG12C (AMG 510) for the Treatment of Solid Tumors
Brian A. Lanman et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
RAS, wanted dead or alive: Advances in targeting RAS mutant cancers
Clint A. Stalnecker et al.
SCIENCE SIGNALING (2020)
Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer
Kirsten L. Bryant et al.
NATURE MEDICINE (2019)
Loss of Sirtuin 1 Alters the Secretome of Breast Cancer Cells by Impairing Lysosomal Integrity
Arash Latifkar et al.
DEVELOPMENTAL CELL (2019)
Combating pancreatic cancer with PI3K pathway inhibitors in the era of personalised medicine
James R. W. Conway et al.
GUT (2019)
KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer
Andrew M. Waters et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2018)
KRAS Suppression-Induced Degradation of MYC Is Antagonized by a MEK5-ERK5 Compensatory Mechanism
Angelina V. Vaseva et al.
CANCER CELL (2018)
Chaperone-mediated autophagy prevents cellular transformation by regulating MYC proteasomal degradation
Luciana R. Gomes et al.
AUTOPHAGY (2017)
The role of CIP2A in cancer: A review and update
Saiedeh Razi Soofiyani et al.
BIOMEDICINE & PHARMACOTHERAPY (2017)
Oncoprotein CIP2A is stabilized via interaction with tumor suppressor PP2A/B56
Jiao Wang et al.
EMBO REPORTS (2017)
All roads lead to PP2A: exploiting the therapeutic potential of this phosphatase
Jaya Sangodkar et al.
FEBS JOURNAL (2016)
BIRC5/Survivin as a target for glycolysis inhibition in high-stage neuroblastoma
J. Hagenbuchner et al.
ONCOGENE (2016)
Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression
Tikvah K. Hayes et al.
CANCER CELL (2016)
The Interaction of Myc with Miz1 Defines Medulloblastoma Subgroup Identity
BaoHan T. Vo et al.
CANCER CELL (2016)
PP2A as a master regulator of the cell cycle
Nathan Wlodarchak et al.
CRITICAL REVIEWS IN BIOCHEMISTRY AND MOLECULAR BIOLOGY (2016)
The Enrichment of Survivin in Exosomes from Breast Cancer Cells Treated with Paclitaxel Promotes Cell Survival and Chemoresistance
Bridget T. Kreger et al.
CANCERS (2016)
YM155 down-regulates survivin and XIAP, modulates autophagy and induces autophagy-dependent DNA damage in breast cancer cells
S. M. Cheng et al.
BRITISH JOURNAL OF PHARMACOLOGY (2015)
Survivin modulates genes with divergent molecular functions and regulates proliferation of hematopoietic stem cells through Evi-1
S. Fukuda et al.
LEUKEMIA (2015)
Survivin and YM155: How faithful is the liaison?
Anke Rauch et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2014)
Targeting Survivin in Cancer: Novel Drug Development Approaches
Bernd Groner et al.
BIODRUGS (2014)
Survivin expression promotes VEGF-induced tumor angiogenesis via PI3K/Akt enhanced β-catenin/Tcf-Lef dependent transcription
Jaime G. Fernandez et al.
MOLECULAR CANCER (2014)
Targeting Inhibitors of the Tumor Suppressor PP2A for the Treatment of Pancreatic Cancer
Amy S. Farrell et al.
MOLECULAR CANCER RESEARCH (2014)
Differential localization and high expression of SURVIVIN splice variants in human embryonic stem cells but not in differentiated cells implicate a role for SURVIVIN in pluripotency
Amber N. Mull et al.
STEM CELL RESEARCH (2014)
MYC Degradation
Amy S. Farrell et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2014)
A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer
R. J. Kelly et al.
ANNALS OF ONCOLOGY (2013)
Depletion of K-Ras promotes proteasome degradation of survivin
Awet Tecleab et al.
CELL CYCLE (2013)
Oncogenic Kras Maintains Pancreatic Tumors through Regulation of Anabolic Glucose Metabolism
Haoqiang Ying et al.
CELL (2012)
Interleukin Enhancer-binding Factor 3/NF110 Is a Target of YM155, a Suppressant of Survivin
Naoto Nakamura et al.
MOLECULAR & CELLULAR PROTEOMICS (2012)
c-Myc activates BRCA1 gene expression through distal promoter elements in breast cancer cells
Yinghua Chen et al.
BMC CANCER (2011)
In Vitro Cytotoxicity and In Vivo Efficacy, Pharmacokinetics, and Metabolism of 10074-G5, a Novel Small-Molecule Inhibitor of c-Myc/Max Dimerization
Dana M. Clausen et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2010)
Phase I Study of YM155, a Novel Survivin Suppressant, in Patients with Advanced Solid Tumors
Taroh Satoh et al.
CLINICAL CANCER RESEARCH (2009)
Survivin: Key regulator of mitosis and apoptosis and novel target for cancer therapeutics
Alain C. Mita et al.
CLINICAL CANCER RESEARCH (2008)
The itinerary of autophagosomes: From peripheral formation to kiss-and-run fusion with lysosomes
Luca Jahreiss et al.
TRAFFIC (2008)
Multiple pathways regulated by the tumor suppressor PP2A in transformation
Jukka Westermarck et al.
TRENDS IN MOLECULAR MEDICINE (2008)
YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts
Takahito Nakahara et al.
CANCER RESEARCH (2007)
CIP2A inhibits PP2A in human malignancies
Melissa R. Junttila et al.
CELL (2007)
Role of post-translational modifications in regulating c-Myc proteolysis, transcriptional activity and biological function
Stephen R. Hann
SEMINARS IN CANCER BIOLOGY (2006)
c-Myc phosphorylation is required for cellular response to oxidative stress
B Benassi et al.
MOLECULAR CELL (2006)
Survivin mediates targeting of the chromosomal passenger complex to the centromere and midbody
G Vader et al.
EMBO REPORTS (2006)
Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability
R Sears et al.
GENES & DEVELOPMENT (2000)
Share Paper
